Status:
COMPLETED
Lasix for the Prevention of De Novo Postpartum Hypertension
Lead Sponsor:
Columbia University
Conditions:
Postpartum Pregnancy-Induced Hypertension
Postpartum Preeclampsia
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high...
Detailed Description
Hypertensive disorders of pregnancy are one of the leading causes of maternal morbidity and mortality worldwide. The majority of clinical research has focused on pregnancy-related hypertension that de...
Eligibility Criteria
Inclusion
- Postpartum women
- No antenatal diagnosis of hypertensive disorder of pregnancy at the time of admission for delivery, defined as existing chronic hypertension diagnosis or documented blood pressure of ≥140 systolic OR ≥90 diastolic on at least 2 occasions at least 4 hours apart prior to delivery admission who do not go on to get magnesium for seizure prophylaxis by the time of delivery
- At least 18 years of age
- English or Spanish speakers
- One or more high risk factors for development of de novo postpartum hypertension
Exclusion
- Non-English or Spanish speakers
- Women with a contraindication to diuretic therapy
- Women who have used diuretics in the two weeks prior to delivery
Key Trial Info
Start Date :
October 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2022
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04752475
Start Date
October 20 2021
End Date
May 28 2022
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center
New York, New York, United States, 10032